Alerts will be sent to your verified email
Verify Email
HESTERBIO
|
Hester Biosciences
|
NGL Fine-Chem
|
Bajaj Healthcare
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
R&D as a % of Total Sales
|
1.91 % | 1.8 % | 1.2 % |
|
Financials
|
|||
|
5 yr Average ROE
|
10.99 % | 18.68 % | 8.79 % |
|
5yr average Equity Multiplier
|
2.14 | 1.37 | 2.22 |
|
5yr Average Asset Turnover Ratio
|
0.46 | 1.03 | 0.84 |
|
5yr Avg Net Profit Margin
|
11.57 % | 12.56 % | 3.88 % |
|
Price to Book
|
3.76 | 3.6 | 2.2 |
|
P/E
|
31.06 | 52.26 | 20.44 |
|
5yr Avg Cash Conversion Cycle
|
60.38 Days | 24.74 Days | 130.36 Days |
|
Inventory Days
|
100.79 Days | 47.94 Days | 89.93 Days |
|
Days Receivable
|
89.02 Days | 84.83 Days | 145.27 Days |
|
Days Payable
|
127.62 Days | 83.75 Days | 94.44 Days |
|
5yr Average Interest Coverage Ratio
|
6.96 | 25.7 | 6.35 |
|
5yr Avg ROCE
|
11.14 % | 24.83 % | 22.78 % |
|
5yr Avg Operating Profit Margin
|
22.71 % | 18.08 % | 17.36 % |
|
5 yr average Debt to Equity
|
0.75 | 0.16 | 0.86 |
|
5yr CAGR Net Profit
|
-4.4 % | -18.08 % | -13.82 % |
|
5yr Average Return on Assets
|
5.28 % | 13.76 % | 4.81 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
53.73 % | 72.74 % | 59.19 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.0 | -1.07 % | -8.23 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.03 % | 0.0 | 1.66 % |
|
Hester Biosciences
|
NGL Fine-Chem
|
Bajaj Healthcare
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Distribution Channel
|
Distribution Channel
|
-
|
-
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
|
Capex
|
Capex
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|